Zai Lab Limited, a biopharmaceutical company listed on the Hong Kong Stock Exchange and NASDAQ, has announced the grant of Restricted Share Units under its 2024 Equity Incentive Plan. On May 12, 2025, U.S. Eastern Time, the company awarded 9,800 American Depositary Shares (ADSs) to two grantees. Following this allocation, 82,686,733 shares remain available for future grants under the plan. This move is part of the company's ongoing efforts to align with its equity compensation strategy, as approved during the 2024 annual general meeting of shareholders.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。